Rigel Pharmaceuticals Inc – Strategy, SWOT and Corporate Finance Report
- Pages: 45
- Published: July 2019
- Report Code: MLPH32587FSA
Rigel Pharmaceuticals Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca, Kissei, Grifols, Merck, Novartis and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.
Scope
Detailed information on Rigel Pharmaceuticals Inc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Rigel Pharmaceuticals Inc in the form of a SWOT analysis
An in-depth view of the business model of Rigel Pharmaceuticals Inc including a breakdown and examination of key business segments
News about Rigel Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Rigel Pharmaceuticals Inc and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Rigel Pharmaceuticals Inc as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Rigel Pharmaceuticals Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Novartis AG
Momenta Pharmaceuticals Inc
Gilead Sciences Inc
Genentech Inc
Emergent BioSolutions Inc
Amgen Inc
AbbVie Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.